Compare AbbVie Inc (ABBV) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs VanEck Gold Miners ETF — how do they compare? AbbVie Inc trades at $250.09 (market cap $438.19B), while VanEck Gold Miners ETF trades at $91.59. The key difference: AbbVie Inc pays a 2.79% dividend while VanEck Gold Miners ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GDX | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $115.84 |
52-Week Low | $197.38 | $56.60 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
GDX trades at $89.84, up 7.09% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rally and strong miner earnings, though financial ratios are unavailable. The ETF offers diversified exposure to gold mining equities, benefiting from high gold prices and institutional interest.
Outlook is positive due to gold's strength and sector momentum, but risks include volatility from gold price swings and competition from physical gold ETFs. Analyst sentiment is mixed, with some seeing value in miners' underperformance relative to gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
